Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life 1-year results from the FRANCE ABSORB registry

Autor: Hervé Le Breton, Simon Elhadad, Frédéric Marco, Said Ghostine, Sylvain Ranc, Philippe Garot, Jean Fajadet, Luc Maillard, Francois Tarragano, Didier Carrié, Thierry Lefèvre, Pascal Motreff, René Koning, Guillaume Cayla, Joel Sainsous
Přispěvatelé: Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Université de Montpellier (UM), Clinique Saint-Hilaire [Rouen], Clinique Pasteur, Clinique Pasteur [Toulouse], Clinique Rhône Durance, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier de Lagny-Marne-la-Vallée, Hôpital Américain de Paris, Hôpital Privé Jacques Cartier [Massy], Institut Cardiovasculaire Paris Sud, Centre Jacques Cartier, Centre hospitalier Saint Joseph - Saint Luc [Lyon], Centre Chirurgical Marie Lannelongue (CCML), Centre Hospitalier Privé Claude Galien - Ramsay Santé, Polyclinique Du Parc, parent, CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, CIC-IT Rennes, Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Hôpital de Rangueil, CHU Toulouse [Toulouse], Centre chirurgical Marie Lannelongue, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Adult
Male
Acute coronary syndrome
medicine.medical_specialty
Percutaneous
Time Factors
medicine.medical_treatment
Psychological intervention
Myocardial Infarction
030204 cardiovascular system & hematology
Prosthesis Design
Percutaneous coronary intervention
03 medical and health sciences
0302 clinical medicine
Recurrence
Risk Factors
Diabetes mellitus
Absorbable Implants
medicine
Clinical endpoint
Humans
030212 general & internal medicine
Myocardial infarction
Angina
Unstable
Prospective Studies
Registries
Angioplasty
Balloon
Coronary
Aged
business.industry
Coronary Thrombosis
Angioplastie coronaire
General Medicine
Stent bioresorbable
Middle Aged
medicine.disease
Syndrome coronaire aigu
Thrombosis
3. Good health
Surgery
Treatment Outcome
Bioresorbable scaffolds
Female
[SDV.IB]Life Sciences [q-bio]/Bioengineering
France
Cardiology and Cardiovascular Medicine
business
[SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing
Zdroj: Archives of cardiovascular diseases
Archives of cardiovascular diseases, 2019, 112 (2), pp.113-123. ⟨10.1016/j.acvd.2018.09.007⟩
Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2019, 112 (2), pp.113-123. ⟨10.1016/j.acvd.2018.09.007⟩
ISSN: 1875-2136
1875-2128
Popis: International audience; Background - Several randomized studies have shown that bioresorbable vascular scaffold (BVS) technology is associated with an increased risk of stent thrombosis. Aim - This study aimed to assess the rates of adverse outcomes at 1 year in patients treated with the Absorb BVS (Abbott Vascular, Santa Clara, CA, USA), using data from a large nationwide prospective multicentre registry (FRANCE ABSORB). Methods - All patients receiving the Absorb BVS in France were included prospectively in the study. Predilatation, optimal sizing and postdilatation were recommended systematically. The primary endpoint was a composite of cardiovascular death, myocardial infarction and target lesion revascularization at 1 year. Secondary endpoints were scaffold thrombosis and target vessel revascularization at 1 year. Results - A total of 2072 patients at 86 centres were included: mean age 55±11 years; 80% men. The indication was acute coronary syndrome (ACS) in 49% of cases. Predilatation and postdilatation were done in 93% and 83% of lesions, respectively. At 1 year, the primary endpoint occurred in 3.9% of patients, the rate of scaffold thrombosis was 1.5% and the rate of target vessel revascularization was 3.3%. In a multivariable analysis, diabetes and total Absorb BVS length>30mm were independently associated with the occurrence of the primary endpoint, whereas oral anticoagulation and total Absorb BVS length>30mm were independently associated with occurrence of scaffold thrombosis. Conclusions - The Absorb BVS was implanted in a relatively young population, half of whom had ACS. Predilatation and postdilatation rates were high, and 1-year outcomes were acceptable.
Databáze: OpenAIRE
Externí odkaz: